Atlas Trials

Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)

Clinical trial NCT04727853 · COMPLETED

Trial details

NCT number
NCT04727853
Sponsor
CSPC Ouyi Pharmaceutical Co., Ltd.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Small Cell Lung Cancer (SCLC)
Start date
2021-03-01
Primary completion
2022-04-26
Enrollment
66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.